A real-world study on growth hormone treatment for children with Bartter syndrome and growth and development disorders

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500099658

Enrollment

Unknown

Registered

2025-03-26

Start date

2025-04-01

Completion date

Unknown

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bartter syndrome

Interventions

Growth hormone treatment group:Growth hormone therapy

Eligibility

Sex/Gender

All

Age

2 Years to 14 Years

Inclusion criteria

Inclusion criteria: (1) Meet the clinical diagnostic criteria for Bartter syndrome; (2) Height is below -2 standard deviation of normal children of the same race, age and gender, or shows growth retardation (annual growth rate = 2 years and <= 14 years; (4) Girls have bone age <= 10 years old or boys have bone age <= 11 years old; (5) Children before puberty (Tanner stage 1); (6) Height growth is not satisfactory after conventional treatments such as potassium supplementation and COX inhibitors; (7) No growth hormone drugs have been used previously; (8) Parents/guardians have agreed for the child to participate in this study and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Abnormal liver function (ALT > 1.5 times the upper limit of normal value, Cr > 1.5 times the upper limit of normal value); (2) Those with positive anti-HBc, HBsAg and HBeAg in hepatitis B virus detection; (3) Those with known highly allergic constitution and allergic to drugs or excipients; (4) Those with diabetes, severe heart and lung diseases, blood system diseases, malignant tumors, systemic infections, low immune function, and mental illness patients; (5) Other types of abnormal growth and development, such as Turner syndrome, Laron syndrome, growth hormone receptor deficiency, etc.; (6) Patients with completely closed epiphyseal plates; (7) Those who have participated in other drug clinical trials within 3 months; (8) Any other conditions that the investigator considers unsuitable for inclusion in the study;

Design outcomes

Primary

Measure	Time frame
Height;	—

Secondary

Measure	Time frame
Growth rate;Insulin-like growth factor 1 standard deviation change;	—

Countries

China

Contacts

Public ContactJiang Hongkun

The First Hospital of China Medical University

jianghongkun007@163.com+86 139 0982 2709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026